J&J Reports 77% Response Rate For Rybrevant Faspro In First-Line Head And Neck Cancer
Oct 25 (Reuters) - Johnson & Johnson JNJ.N:
J&J - JNJ REPORTS 77% RESPONSE RATE FOR RYBREVANT FASPRO IN FIRST-LINE HEAD AND NECK CANCER
Source text: [ID:]
Further company coverage: JNJ.N